Analysts’ Recent Ratings Updates for Allscripts Healthcare Solutions (MDRX)

Allscripts Healthcare Solutions (NASDAQ: MDRX) has recently received a number of price target changes and ratings updates:

  • 1/28/2018 – Allscripts Healthcare Solutions had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $17.00 price target on the stock. They wrote, “Last week, an article on FierceHealthcare.com suggested that an ongoing DOJ investigation had affected the purchase price paid by Allscripts for Practice Fusion.””
  • 1/25/2018 – Allscripts Healthcare Solutions was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Allscripts has had a favorable run on the bourses over the last year, trading above the broader industry. The company’s solid growth in U.S. Core Solutions and Services holds promise at the moment. Allscripts Sunrise electronic health record (EHR) platform and Revenue Cycle Management Services are likely to drive the company’s top line in the quarters to come. Also, Allscripts has a leading market share in inpatient and ambulatory settings. Allscripts announced a definitive agreement to buy Practice Fusion for $100 million in cash. However, the company’s continued reliance on mergers and acquisition activities poses substantial integration risks. Intensifying competition is a major dampener. The company’s products have a long sales cycle which involves intensive decision-making at different managerial levels. Allscripts also expects a modest increase in operating expenses to support business growth over the long haul.”
  • 1/19/2018 – Allscripts Healthcare Solutions was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 1/18/2018 – Allscripts Healthcare Solutions is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $17.50 price target on the stock.
  • 1/16/2018 – Allscripts Healthcare Solutions was downgraded by analysts at SunTrust Banks, Inc. from a “buy” rating to a “hold” rating. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 1/12/2018 – Allscripts Healthcare Solutions was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Allscripts has had a favorable run on the bourses over the last year, trading above the broader industry. However, the company’s continued reliance on mergers and acquisition activities poses substantial integration risks. Further, intensifying competition is a major dampener. The company’s products have a long sales cycle which involves intensive decision-making at different managerial levels. The company also expects a modest increase in operating expenses to support business growth. On a positive note, a solid guidance for 2017 and an encouraging long-term outlook are the key highlights of the quarter. Also, the expansion in margin is encouraging. The company’s solid growth in U.S. Core Solutions and Services, fueled by Sunrise electronic health record (EHR) platform and Allscripts Revenue Cycle Management Services, buoys optimism.”
  • 1/11/2018 – Allscripts Healthcare Solutions was given a new $19.00 price target on by analysts at Royal Bank of Canada. They now have a “buy” rating on the stock.
  • 1/9/2018 – Allscripts Healthcare Solutions had its “buy” rating reaffirmed by analysts at Maxim Group. They now have a $20.00 price target on the stock. They wrote, “MDRX announced the acquisition of Practice Fusion, a provider of cloud- based electronic health record (EHR) platforms, for $100M in cash. The acquisition is expected to close in 1Q18. We believe Practice Fusion was sold at 1.0x-2.0x revenue, implying a $50M- $100M revenue run rate. It is expected to be marginally accretive in 2018. We estimate that the company’s recently-acquired Enterprise Information Systems (EIS) business is operating at a roughly $400M-$450M revenue run rate, significantly above our original estimate of $300M. We believe attrition in the EIS business may be lower than originally projected.””
  • 1/8/2018 – Allscripts Healthcare Solutions had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $17.00 price target on the stock. They wrote, “This morning, Allscripts announced that it would acquire Practice Fusion, a web-based EHR application targeted at small physician groups.””
  • 1/4/2018 – Allscripts Healthcare Solutions is now covered by analysts at Citigroup Inc. They set a “buy” rating on the stock.
  • 12/20/2017 – Allscripts Healthcare Solutions was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.

Shares of Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) opened at $15.34 on Monday. The firm has a market cap of $2,771.65, a PE ratio of -13.22, a PEG ratio of 2.22 and a beta of 1.33. The company has a quick ratio of 0.98, a current ratio of 0.98 and a debt-to-equity ratio of 1.20. Allscripts Healthcare Solutions Inc has a fifty-two week low of $11.25 and a fifty-two week high of $16.13.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last announced its quarterly earnings data on Thursday, November 2nd. The software maker reported $0.12 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.12. Allscripts Healthcare Solutions had a negative net margin of 12.23% and a positive return on equity of 6.53%. The firm had revenue of $451.20 million during the quarter, compared to analysts’ expectations of $429.94 million. sell-side analysts expect that Allscripts Healthcare Solutions Inc will post 0.46 EPS for the current year.

In related news, EVP Brian Farley sold 5,000 shares of the firm’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $14.35, for a total value of $71,750.00. Following the completion of the sale, the executive vice president now owns 191,607 shares in the company, valued at $2,749,560.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP James Hewitt sold 36,796 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $14.11, for a total transaction of $519,191.56. Following the completion of the sale, the senior vice president now owns 181,766 shares of the company’s stock, valued at approximately $2,564,718.26. The disclosure for this sale can be found here. Insiders sold 56,796 shares of company stock valued at $804,842 in the last quarter. Company insiders own 0.91% of the company’s stock.

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Receive News & Ratings for Allscripts Healthcare Solutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply